Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases

Abstract

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL- 4 expression in EL- 4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL- 1 , TNF-α, or MIP- 2 , thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

1 . A pharmaceutical composition comprising a monoacetyldiacylglycerol compound of Formula 1 as an active ingredient for preventing or treating chronic obstructive pulmonary disease. 
       
         
           
           
               
               
           
         
         wherein R1 and R2 are independently a fatty acid group of 14 to 20 carbon atoms. 
       
     
     
         2 . The composition according to  claim 1 , wherein R1 and R2 are independently selected from the group consisting of palmitoyl, oleoyl, linoleoyl, linolenoyl, stearoyl, myristoyl, and arachidonoyl. 
     
     
         3 . The composition according to  claim 1 , wherein R1 and R2 (R1/R2) is selected from the group consisting of oleoyl/palmitoyl, palmitoyl/oleoyl, palmitoyl/linoleoyl, palmitoyl/linolenoyl, palmitoyl/arachidonoyl, palmitoyl/stearoyl, palmitoyl/palmitoyl, oleoyl/stearoyl, linoleoyl/palmitoyl, linoleoyl/stearoyl, stearoyl/linoleoyl, stearoyl/oleoyl, myristoyl/linoleoyl, myristoyl/oleoyl. 
     
     
         4 . The composition according to  claim 1 , wherein the monoacetyldiacylglycerol compound is a compound of Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The composition according to  claim 1 , wherein the monoacetyldiacylglycerol compound of Formula 1 is separated and extracted from natural deer antler. 
     
     
         6 . The composition according to  claim 1 , wherein chronic obstructive pulmonary disease is chronic bronchitis or emphysema. 
     
     
         7 . The composition according to  claim 1 , wherein the monoacetyldiacylglycerol compound reduces the secretion of one or more protein selected from a group consisting of IL-4, CXCL-1, TNF-α and MIP-2 levels. 
     
     
         8 . The composition according to  claim 1 , wherein the monoacetyldiacylglycerol compound reduces the number of inflammatory cells around the bronchi or vessels or the numbers of CD4 +  cells and Gr-1 +  neutrophils 
     
     
         9 . The composition according to  claim 1 , wherein the monoacetyldiacylglycerol compound of formula 1 is in an amount of 0.001 to 50% by weight of the composition. 
       
         
           
           
               
               
           
         
         wherein R1 and R2 are independently a fatty acid group of 14 to 20 carbon atoms. 
       
     
     
         10 . A health functional food composition comprising a monoacetyldiacylglycerol compound of Formula 1 as an active ingredient for preventing or alleviating chronic obstructive pulmonary disease. 
       
         
           
           
               
               
           
         
         wherein R1 and R2 are independently a fatty acid group of 14 to 20 carbon atoms. 
       
     
     
         11 . The composition according to  claim 10 , wherein R1 and R2 are independently selected from the group consisting of palmitoyl, oleoyl, linoleoyl, linolenoyl, stearoyl, myristoyl, and arachidonoyl. 
     
     
         12 . The composition according to  claim 10 , wherein R1 and R2 (R1/R2) is selected from the group consisting of oleoyl/palmitoyl, palmitoyl/oleoyl, palmitoyl/linoleoyl, palmitoyl/linolenoyl, palmitoyl/arachidonoyl, palmitoyl/stearoyl, palmitoyl/palmitoyl, oleoyl/stearoyl, linoleoyl/palmitoyl, linoleoyl/stearoyl, stearoyl/linoleoyl, stearoyl/oleoyl, myristoyl/linoleoyl, myristoyl/oleoyl. 
     
     
         13 . A method for preventing or treating chronic obstructive pulmonary disease, comprising administering to a non-human object the composition according to  claim 1 .